Special correlation between diet and MASLD: positive or negative?
- PMID: 40221799
- PMCID: PMC11992798
- DOI: 10.1186/s13578-025-01382-1
Special correlation between diet and MASLD: positive or negative?
Abstract
Metabolic dysfunction-associated steatotic liver disease (MASLD) is a chronic and systemic metabolic liver disease characterized by the presence of hepatic steatosis and at least one cardiometabolic risk factor (CMRF). The pathogenesis of MASLD involves multiple mechanisms, including lipid metabolism disorders, insulin resistance, inflammatory responses, and the hepato-intestinal axis of metabolic dysfunction. Among these factors, diet serves as both an inducement and a potential remedy in the disease's development. Notably, a high-lipid diet exacerbates fat accumulation, oxidative stress, and inflammatory responses, thereby promoting the progression of MASLD. Consequently, dietary induction models have become vital tools for studying the pathological mechanisms of MASLD, providing a foundation for identifying potential therapeutic targets. Additionally, we summarize the therapeutic effects of dietary optimization on MASLD and elucidate the role of specific dietary components in regulating the hepato-intestinal axis, lipid metabolism, and inhibiting inflammatory responses. In conclusion, studies utilizing animal models of MASLD offer significant insights into dietary therapy, particularly concerning the regulation of lipid metabolism-related and hepatoenteric axis-related signaling pathways as well as the beneficial mechanism of probiotics in hepatoenteric regulation. By understanding the specific mechanisms by which different dietary patterns affect MASLD, we can assess the clinical applicability of current dietary strategies and provide new directions for research and treatment aimed at disease modification.
Keywords: Curative strategy; Dietary models; Dietary therapy; Hepato-intestinal axis; MASLD; Pathological mechanism.
© 2025. The Author(s).
Conflict of interest statement
Declarations. Competing interests: The authors have declared that no competing interest exists.
Figures


Similar articles
-
Dietary inflammatory potential and metabolic (dysfunction)-associated steatotic liver disease and its complications: A comprehensive review.Clin Nutr ESPEN. 2025 Feb;65:162-171. doi: 10.1016/j.clnesp.2024.11.032. Epub 2024 Nov 26. Clin Nutr ESPEN. 2025. PMID: 39608495 Review.
-
Vitamin D and Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): Novel Mechanistic Insights.Int J Mol Sci. 2024 Apr 30;25(9):4901. doi: 10.3390/ijms25094901. Int J Mol Sci. 2024. PMID: 38732118 Free PMC article. Review.
-
Dietary Influences on Gut Microbiota and Their Role in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).Nutrients. 2024 Dec 31;17(1):143. doi: 10.3390/nu17010143. Nutrients. 2024. PMID: 39796579 Free PMC article. Review.
-
Hepatic miR-149-5p upregulation fosters steatosis, inflammation and fibrosis development in mice and in human liver organoids.JHEP Rep. 2024 Jun 4;6(9):101126. doi: 10.1016/j.jhepr.2024.101126. eCollection 2024 Sep. JHEP Rep. 2024. PMID: 39263327 Free PMC article.
-
Helicobacter pylori infection exacerbates metabolic dysfunction-associated steatotic liver disease through lipid metabolic pathways: a transcriptomic study.J Transl Med. 2024 Jul 29;22(1):701. doi: 10.1186/s12967-024-05506-y. J Transl Med. 2024. PMID: 39075482 Free PMC article.
Cited by
-
Alistipes putredinis Ameliorates Metabolic Dysfunction-Associated Steatotic Liver Disease in Rats via Gut Microbiota Remodeling and Inflammatory Suppression.Nutrients. 2025 Jun 16;17(12):2013. doi: 10.3390/nu17122013. Nutrients. 2025. PMID: 40573124 Free PMC article.
-
Endarachne binghamiae Ameliorates Hepatic Steatosis, Obesity, and Blood Glucose via Modulation of Metabolic Pathways and Oxidative Stress.Int J Mol Sci. 2025 May 26;26(11):5103. doi: 10.3390/ijms26115103. Int J Mol Sci. 2025. PMID: 40507912 Free PMC article.
References
-
- Targher G, Byrne CD, Tilg H. MASLD: a systemic metabolic disorder with cardiovascular and malignant complications. Gut. 2024;73(4):691–702. - PubMed
-
- Scoditti E, Sabatini S, Carli F, Gastaldelli A. Hepatic glucose metabolism in the steatotic liver. Nat Rev Gastroenterol Hepatol. 2024;21(5):319–34. - PubMed
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources